Generated September 19, 2026.
Overview
ARKG and HLTH are both actively managed healthcare-focused equity ETFs, but they target distinct innovation themes. ARKG concentrates on genomics, gene editing, CRISPR, and molecular diagnostics — companies working on the biological foundations of disease. HLTH, launched much more recently, focuses on artificial intelligence applications across healthcare, including drug discovery, diagnostics, medical imaging, and IT platforms. Both charge 0.75%, but differ sharply in scale, track record, and underlying thesis.
How they differ
The first and most significant difference is maturity and assets under management. ARKG has been operating since 10/31/2014 and manages $1.93B, while HLTH launched on 07/21/2026 with just $8.67M — a roughly 220-fold difference in deployed capital.
Second, their innovation exposures point in different directions. ARKG's genomics and CRISPR focus is on molecular biology and precision medicine — relatively established innovation themes with visible clinical pipelines. HLTH's AI-healthcare bet is broader but earlier-stage, spanning nascent applications across drug discovery, imaging analysis, and healthcare software. These may overlap in holdings but target fundamentally different technology adoption curves.
Third, volatility profiles differ measurably. ARKG reports a beta of 2.37, indicating roughly 2.4 times the volatility of the broad market — typical for genomics and gene-therapy exposure, where clinical trial results and regulatory approval swings drive large price moves. Both charge identical fees at 0.75%, so cost is not a differentiator.
Who each is best for
ARKG: Fits investors with a long time horizon who want exposure to genomic innovation and can tolerate elevated equity volatility. The track record spanning a decade provides evidence of how the strategy has performed across multiple market environments.
HLTH: Fits investors with conviction in AI applications transforming healthcare delivery and diagnostics, and who can accept the risk profile of a newly launched fund with no operational history. Early entry into a nascent theme appeals to investors comfortable with unproven execution.
Key risks to know
- Concentrated thematic exposure: Both funds bet heavily on specific healthcare innovation narratives (genomics vs. AI) rather than broad sector diversification. If either theme disappoints clinically, regulatorily, or commercially, concentrated losses can follow.
- High volatility in genomics and early-stage healthcare: ARKG's beta of 2.37 means it amplifies market downturns and sector corrections. An AI-focused healthcare portfolio would likely exhibit similar or greater volatility given the nascency of the applications.
- Unproven strategy with no live performance history: HLTH has operated for less than a month. Its manager's ability to identify and weight high-conviction AI-healthcare positions, rebalance through market stress, and avoid value-destructive trades is entirely untested. Smaller funds face higher operational friction and may struggle to sustain investor interest if early performance disappoints.
Bottom line
If you want established genomic-medicine exposure with a decade of track record, ARKG offers scale and history at the cost of significant volatility. Past performance does not predict future results.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.
